Literature DB >> 10628332

Cholesteryl butyrate in solid lipid nanospheres as an alternative approach for butyric acid delivery.

C Pellizzaro1, D Coradini, S Morel, E Ugazio, M R Gasco, M G Daidone.   

Abstract

BACKGROUND: Cholesteryl-butyrate chosen as lipid matrix of solid lipid nanospheres (SLNs) could be a suitable pro-drug to deliver butyric acid and overcome one of the most limiting disadvantages of the compound: the short half-life due to a rapid metabolism.
METHODS: We evaluated the antiproliferative effect, with respect to that of sodium butyrate, of four SLNs (SLN1, SLN2, SLN3 and SLN4) characterized by a different concentration of cholesteryl-butyrate (range, 1.7-30 mM) on NIH-H460, a non-small cell lung carcinoma cell line.
RESULTS: After 6 days of treatment, all SLN preparations induced a dose-dependent inhibition of NHI-H460 cell growth: the most effective SLN preparation (SLN1) was able to induce a complete growth inhibition already at 0.25 mM, a concentration at which sodium butyrate induced only a 55% inhibition. Fluorescence microscopy showed that 6-coumarin-tagged SLNs were almost completely internalized by cells after 5 min of treatment.
CONCLUSIONS: The present results indicate that owing to their peculiar characteristics, SLNs could be an interesting alternative approach for butyric acid delivery into tumor cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10628332

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

Review 1.  Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy.

Authors:  Sebastian Lunke; Assam El-Osta
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

2.  In vitro effects of cholesteryl butyrate solid lipid nanospheres as a butyric acid pro-drug on melanoma cells: evaluation of antiproliferative activity and apoptosis induction.

Authors:  B Salomone; R Ponti; M R Gasco; E Ugazio; P Quaglino; S Osella-Abate; M G Bernengo
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells.

Authors:  R Minelli; L Serpe; P Pettazzoni; V Minero; G Barrera; Cl Gigliotti; R Mesturini; A C Rosa; P Gasco; N Vivenza; E Muntoni; R Fantozzi; U Dianzani; G P Zara; C Dianzani
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion of human neutrophils to endothelial cells.

Authors:  Chiara Dianzani; Roberta Cavalli; Gian Paolo Zara; Margherita Gallicchio; Grazia Lombardi; Maria Rosa Gasco; Patrizia Panzanelli; Roberto Fantozzi
Journal:  Br J Pharmacol       Date:  2006-05-15       Impact factor: 8.739

5.  Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models.

Authors:  R Minelli; S Occhipinti; C L Gigliotti; G Barrera; P Gasco; L Conti; A Chiocchetti; G P Zara; R Fantozzi; M Giovarelli; U Dianzani; C Dianzani
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

6.  Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in an in vivo model.

Authors:  Chiara Dianzani; Federica Foglietta; Benedetta Ferrara; Arianna Carolina Rosa; Elisabetta Muntoni; Paolo Gasco; Carlo Della Pepa; Roberto Canaparo; Loredana Serpe
Journal:  World J Gastroenterol       Date:  2017-06-21       Impact factor: 5.742

Review 7.  Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug.

Authors:  Andrea Brioschi; Gian Paolo Zara; Sara Calderoni; Maria Rosa Gasco; Alessandro Mauro
Journal:  Molecules       Date:  2008-02-01       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.